• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • ObGyn
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • ObGyn
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response

    Thumbnail
    View/ Open
    1479-5876-10-162.PMC3478976.pdf (329.1Kb)

    Show full item record
    
    Author
    Salom, Emery; Penalver, Manuel; Homesley, Howard D.; Burrell, Matthew; Garrett, Audrey; Presant, Cary A.; Rutledge, James; Chernick, Michael; Hallquist, Allan; Perree, Mathieu
    Abstract
    Background This study was performed to determine if a chemotherapy-induced apoptosis assay (MiCK) could predict the best therapy for patients with ovarian cancer. Methods A prospective, multi-institutional and blinded trial of the assay was conducted in 104 evaluable ovarian cancer patients treated with chemotherapy. The MiCK assay was performed prior to therapy, but treating physicians were not told of the results and selected treatment only on clinical criteria. Outcomes (response, time to relapse, and survival) were compared to the drug-induced apoptosis observed in the assay. Results Overall survival in primary therapy, chemotherapy naïve patients with Stage III or IV disease was longer if patients received a chemotherapy which was best in the MiCK assay, compared to shorter survival in patients who received a chemotherapy that was not the best. (p < 0.01, hazard ratio HR 0.23). Multivariate model risk ratio showed use of the best chemotherapy in the MiCK assay was the strongest predictor of overall survival (p < 0.01) in stage III or IV patients. Standard therapy with carboplatin plus paclitaxel (C + P) was not the best chemotherapy in the MiCK assay in 44% of patients. If patients received C + P and it was the best chemotherapy in the MiCK assay, they had longer survival than those patients receiving C + P when it was not the best chemotherapy in the assay (p = 0.03). Relapse-free interval in primary therapy patients was longer if patients received the best chemotherapy from the MiCK assay (p = 0.03, HR 0.52). Response rates (CR + PR) were higher if physicians used an active chemotherapy based on the MiCK assay (p = 0.03). Conclusion The MiCK assay can predict the chemotherapy associated with better outcomes in ovarian cancer patients. This study quantifies outcome benefits on which a prospective randomized trial can be developed.
    URI
    http://hdl.handle.net/10342/5718
    Date
    2012
    Citation:
    APA:
    Salom, Emery, & Penalver, Manuel, & Homesley, Howard D., & Burrell, Matthew, & Garrett, Audrey, & Presant, Cary A., & Rutledge, James, & Chernick, Michael, & Hallquist, Allan, & Perree, Mathieu. (January 2012). Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. Journal of Translational Medicine, (162-162. Retrieved from http://hdl.handle.net/10342/5718

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Salom, Emery, and Penalver, Manuel, and Homesley, Howard D., and Burrell, Matthew, and Garrett, Audrey, and Presant, Cary A., and Rutledge, James, and Chernick, Michael, and Hallquist, Allan, and Perree, Mathieu. "Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response". Journal of Translational Medicine. . (162-162.), January 2012. March 06, 2021. http://hdl.handle.net/10342/5718.
    Chicago:
    Salom, Emery and Penalver, Manuel and Homesley, Howard D. and Burrell, Matthew and Garrett, Audrey and Presant, Cary A. and Rutledge, James and Chernick, Michael and Hallquist, Allan and Perree, Mathieu, "Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response," Journal of Translational Medicine 10, no. (January 2012), http://hdl.handle.net/10342/5718 (accessed March 06, 2021).
    AMA:
    Salom, Emery, Penalver, Manuel, Homesley, Howard D., Burrell, Matthew, Garrett, Audrey, Presant, Cary A., Rutledge, James, Chernick, Michael, Hallquist, Allan, Perree, Mathieu. Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. Journal of Translational Medicine. January 2012; 10() 162-162. http://hdl.handle.net/10342/5718. Accessed March 06, 2021.
    Collections
    • ObGyn

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback